ArticleESMO open2025
The role of whole-genome sequencing for guiding systemic therapy in patients with soft tissue sarcoma.
Article in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Molecular profiling and access to treatment for rare cancers in Europe.Nature communications · 2026Article
- Real-World Implementation of Next-Generation Sequencing in Sarcoma: Molecular Insights and Therapeutic Outcomes.Medical sciences (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe analysis of tumor DNA by whole-genome sequencing (WGS) is increasingly utilized for the identification of clinically relevant DNA aberrations. We aim to assess whether WGS improves the guidance of individualized systemic therapy in soft tissue sarcoma (STS). PATIENTS AND
methodsWGS results of STS patients were retrieved from electronic patient records and pathology reports from clinical studies and routine diagnostics. WGS was carried out in primary STS with an unfavorable prognosis, metastatic STS, or STS where broad molecular diagnostics were deemed necessary. Actionable targets were defined as genomic alterations identified by WGS for which specific systemic therapy was indicated in routine care or clinical trials available at time of the WGS analysis.
resultsWGS was carried out on 161 STS patients. The most common histological subtypes were leiomyosarcoma (22%), undifferentiated pleomorphic sarcoma/sarcoma not otherwise specified (17%) and dedifferentiated liposarcoma (14%). The majority of WGS analyses were requested at the time of recurrence or metastasis (41%), At least one actionable target was found by WGS in 74 (46%) of patients. Actionable targets were more frequently seen for complex genome sarcomas compared with simple genome sarcomas (50% versus 28%). Eventually, 23 patients (14%) received matched experimental therapy based on their WGS results. Non-availability of WGS directed treatment or lack of clinical necessity for systemic therapy (n = 17) and rapid disease progression causing poor performance score (n = 10) were the main reasons to not start WGS-informed therapy.
conclusionWGS identified actionable targets in 46% of STS cases, leading to WGS-informed therapy in 14% of patients. Improving the timing of the WGS request and a more appropriate patient selection upfront could increase this relatively low percentage. Complex genome sarcomas seem to be the STS group for which WGS is most likely to add value by opening the way to tumor-agnostic therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.